共 41 条
- [31] Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Liu, FunanGong, JifangJin, ZhaoyuZhang, MiaoZhang, ShuZhang, YanqiaoLiang, XinjunLi, YunYang, XiaochunYang, YapingShen, Lin
- [32] Letter to the editor for the article 'Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study'INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (09) : 6026 - 6027Wang, LexinWu, QibiaoChi, HaoYang, Guanhu
- [33] Efficacy and safety of neoadjuvant chemoradiotherapy plus apatinib for patients with locally advanced, HER2-negative, Siewert's type II-III adenocarcinoma of esophagogastric junction: a single-arm, open-label, phase II trialAMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (08): : 9015 - 9023Guo, HonghaiLi, YongLin, ChiCheng, YunjieZhang, ZhidongWang, DongZhao, XuefengLiu, YuJing, ShaowuYang, PeigangTian, YuanLiu, YangWang, JunZhao, Qun
- [34] Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Lee, Keun WookIm, Young-HyuckLee, Keun SeokCho, Jae YongOh, Do-YounChung, Hyun Cheol CheolChao, YeeBai, Li-YuanYen, Chia JuiKim, In-HoOh, Sang CheulLin, Chia-ChiWang, JinWang, XinLi, HuiyanChen, Yen-YangKang, Yoon-Koo
- [35] Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER22, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Shitara, KoheiVan Cutsem, EricLordick, FlorianEnzinger, Peter C.Ilson, David H.Shah, Manish A.Xu, Rui-HuaLonardi, SaraYamaguchi, KenseiHung, Yi-PingKukielka-Budny, BozenaBhattacharya, Pranob P.Matsangou, MariaLi, RanMoran, Diarmuid MartinRanganath, RadhikaPophale, RupeshAjani, Jaffer A.
- [36] JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Bang, Yung-JueKang, Yoon-KooAlsina, MariaWeinberg, Zev A.Chau, IanZhu, JinChan, Wai Y.Patel, Premal H.Meng, Raymond D.Ajanl, Jaffer A.
- [37] ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Oh, YounChung, Hyun CheolIm, Young HyuckYen, Chia JuiChao, YeeLi, ZheZhenWang, XinWang, JinLi, HuiyanKang, Yoon-Koo
- [38] A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trialCANCER RESEARCH, 2020, 80 (04)Saji, ShigehiraKitada, MasahiroTakano, ToshimiTakada, MasahiroOhtake, TohruToyama, TatsuyaKikawa, YuichiroHasegawa, YoshieFujisawa, TomomiKashiwaba, MasahiroIshida, TakanoriNakamura, RikiyaYamamoto, YutakaToh, UhiIwata, HirojiMasuda, NorikazuTaira, NarutoMorita, SatoshiOhno, ShinjiToi, Masakazu
- [39] Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trialANNALS OF ONCOLOGY, 2023, 34 : S1542 - S1543Shen, L.Chen, P.Lu, J.Wan, Y.Zheng, Y.Ye, F.Yang, J.Liu, Y.Pan, H.Chen, H.Sun, M.Fan, Q.Yuan, Y.Chen, K.Sun, Z.Tian, H.Ye, X.Peng, Z.
- [40] EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer groupBMC CANCER, 2019, 19Wagner, Anna DorotheaGrabsch, Heike, IMauer, MurielleMarreaud, SandrineCaballero, CarmelaThuss-Patience, PeterMueller, LotharElme, AnnelieMoehler, Markus HermannMartens, UweKang, Yoon-KooRha, Sun YoungCats, AnnemiekeTokunaga, MasanoriLordick, Florian